Review



hcd45 fitc  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Miltenyi Biotec hcd45 fitc
    Hcd45 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 331 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcd45 fitc/product/Miltenyi Biotec
    Average 97 stars, based on 331 article reviews
    hcd45 fitc - by Bioz Stars, 2026-02
    97/100 stars

    Images



    Similar Products

    97
    Miltenyi Biotec hcd45 fitc
    Hcd45 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcd45 fitc/product/Miltenyi Biotec
    Average 97 stars, based on 1 article reviews
    hcd45 fitc - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec human cd45 hcd45 staining
    (A) NSG mice were engrafted with malignant primary cells derived from the bone marrow of 10 T-ALL patients for tumor expansion. Upon disease establishment, mice were sacrificed, and leukemic cells were harvested from the spleen. To mimic biological replicates, six mice were injected per patient. The percentage of human <t>CD45+</t> cells <t>(hCD45%)</t> was measured by flow cytometry, with only samples exceeding 85% used for downstream analysis. Global hPTM profiling and DNA methylation sequencing were performed for all 10 PDX models. In parallel, PDX cells were treated ex vivo with a panel of eight epidrugs to assess drug sensitivity. Spearman correlation analysis was then conducted to explore the relationship between hPTM levels and drug response. Figure created with Biorender.com . (B) Clustered and annotated heatmap displaying the normalized and summarized single hPTM levels across the 10 PDX models. (C) Volcano plot illustrating the differential analysis of hPTMs between CIMPlow and CIMPhigh PDX models.
    Human Cd45 Hcd45 Staining, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd45 hcd45 staining/product/Miltenyi Biotec
    Average 97 stars, based on 1 article reviews
    human cd45 hcd45 staining - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec hcd45
    Selective inhibition of PDGFRB in vivo results in significant leukemia growth delay. (A) % <t>hCD45</t> + cells in peripheral blood at start of treatment (week 0), 1 and 2 weeks after start of treatment analyzed using flow cytometry. (B) % hCD45 + cells in bone marrow at end of treatment (2 weeks) analyzed using flow cytometry. (C) Spleen weight at end of treatment (2 weeks). ** P <0.01, **** P <0.0001.
    Hcd45, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcd45/product/Miltenyi Biotec
    Average 97 stars, based on 1 article reviews
    hcd45 - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    90
    Becton Dickinson hcd45-fitc
    Selective inhibition of PDGFRB in vivo results in significant leukemia growth delay. (A) % <t>hCD45</t> + cells in peripheral blood at start of treatment (week 0), 1 and 2 weeks after start of treatment analyzed using flow cytometry. (B) % hCD45 + cells in bone marrow at end of treatment (2 weeks) analyzed using flow cytometry. (C) Spleen weight at end of treatment (2 weeks). ** P <0.01, **** P <0.0001.
    Hcd45 Fitc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcd45-fitc/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    hcd45-fitc - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec anti human cd45 hcd45 viobright fitc
    Selective inhibition of PDGFRB in vivo results in significant leukemia growth delay. (A) % <t>hCD45</t> + cells in peripheral blood at start of treatment (week 0), 1 and 2 weeks after start of treatment analyzed using flow cytometry. (B) % hCD45 + cells in bone marrow at end of treatment (2 weeks) analyzed using flow cytometry. (C) Spleen weight at end of treatment (2 weeks). ** P <0.01, **** P <0.0001.
    Anti Human Cd45 Hcd45 Viobright Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human cd45 hcd45 viobright fitc/product/Miltenyi Biotec
    Average 97 stars, based on 1 article reviews
    anti human cd45 hcd45 viobright fitc - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec human cd45 hcd45 staining staining cd45 fitc antibody
    T-LBL PDX models are sensitive towards in vivo treatment with decitabine. ( A ) T-LBL develops in lymphatic tissues such as the lymph nodes. In T-LBL cells, the DNA methylation pattern is hypermethylated compared to healthy cells. Upon replication, decitabine (DAC) can incorporate into the DNA and irreversibly bind to DNA methyl transferases (DNMTs), thereby countering hypermethylation and restoring transcription. Figure created with BioRender.com . ( B ) NSG mice injected with malignant pleural effusions from patients with T-LBL were treated with vehicle (PBS with 1% DMSO, blue) or decitabine (DAC 0.5 mg/kg body weight, orange). Once engraftment was successful (1% <t>hCD45</t> + cells in the peripheral blood), mice were treated for one or two cycles for five consecutive treatment days followed by two days off. Mice were followed for survival analysis and leukemia burden in the blood. Figure created with BioRender.com . ( C ) Kaplan–Meier analysis of lymphoma-free survival after decitabine treatment (start of treatment is marked with a syringe) is shown (log-rank Mantel-Cox test; p -values: 0.1234 (ns), 0.0332 (*), 0.0021 (**), 0.0002 (***)) for the five T-LBL PDX models analyzed. One treatment cycle (dotted lines) and two treatment cycles (full lines) are compared. ( D ) The treatment effect of 1 cycle of decitabine on hCD45 + cells in the peripheral blood is shown by normalizing tumor growth (average #hCD45 + cells on day 5/average #hCD45 + cells on day 1) in decitabine treated mice to tumor growth in vehicle treated mice.
    Human Cd45 Hcd45 Staining Staining Cd45 Fitc Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd45 hcd45 staining staining cd45 fitc antibody/product/Miltenyi Biotec
    Average 97 stars, based on 1 article reviews
    human cd45 hcd45 staining staining cd45 fitc antibody - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    86
    Thermo Fisher anti hcd45 fitc
    Characterization of the chimeric immune system.
    Anti Hcd45 Fitc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti hcd45 fitc/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    anti hcd45 fitc - by Bioz Stars, 2026-02
    86/100 stars
      Buy from Supplier

    90
    Thermo Fisher hcd45-fitc
    Characterization of the chimeric immune system.
    Hcd45 Fitc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcd45-fitc/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    hcd45-fitc - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) NSG mice were engrafted with malignant primary cells derived from the bone marrow of 10 T-ALL patients for tumor expansion. Upon disease establishment, mice were sacrificed, and leukemic cells were harvested from the spleen. To mimic biological replicates, six mice were injected per patient. The percentage of human CD45+ cells (hCD45%) was measured by flow cytometry, with only samples exceeding 85% used for downstream analysis. Global hPTM profiling and DNA methylation sequencing were performed for all 10 PDX models. In parallel, PDX cells were treated ex vivo with a panel of eight epidrugs to assess drug sensitivity. Spearman correlation analysis was then conducted to explore the relationship between hPTM levels and drug response. Figure created with Biorender.com . (B) Clustered and annotated heatmap displaying the normalized and summarized single hPTM levels across the 10 PDX models. (C) Volcano plot illustrating the differential analysis of hPTMs between CIMPlow and CIMPhigh PDX models.

    Journal: bioRxiv

    Article Title: Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia

    doi: 10.1101/2025.09.01.673463

    Figure Lengend Snippet: (A) NSG mice were engrafted with malignant primary cells derived from the bone marrow of 10 T-ALL patients for tumor expansion. Upon disease establishment, mice were sacrificed, and leukemic cells were harvested from the spleen. To mimic biological replicates, six mice were injected per patient. The percentage of human CD45+ cells (hCD45%) was measured by flow cytometry, with only samples exceeding 85% used for downstream analysis. Global hPTM profiling and DNA methylation sequencing were performed for all 10 PDX models. In parallel, PDX cells were treated ex vivo with a panel of eight epidrugs to assess drug sensitivity. Spearman correlation analysis was then conducted to explore the relationship between hPTM levels and drug response. Figure created with Biorender.com . (B) Clustered and annotated heatmap displaying the normalized and summarized single hPTM levels across the 10 PDX models. (C) Volcano plot illustrating the differential analysis of hPTMs between CIMPlow and CIMPhigh PDX models.

    Article Snippet: Lymphoblast engraftment and leukemic burden was monitored by flow cytometric analysis on peripheral blood, using human CD45+ (hCD45) staining (CD45-FITC antibody; Miltenyi Biotec, Bergish Gladbag, Germany).

    Techniques: Derivative Assay, Injection, Flow Cytometry, DNA Methylation Assay, Sequencing, Ex Vivo

    Selective inhibition of PDGFRB in vivo results in significant leukemia growth delay. (A) % hCD45 + cells in peripheral blood at start of treatment (week 0), 1 and 2 weeks after start of treatment analyzed using flow cytometry. (B) % hCD45 + cells in bone marrow at end of treatment (2 weeks) analyzed using flow cytometry. (C) Spleen weight at end of treatment (2 weeks). ** P <0.01, **** P <0.0001.

    Journal: Haematologica

    Article Title: Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma

    doi: 10.3324/haematol.2023.283981

    Figure Lengend Snippet: Selective inhibition of PDGFRB in vivo results in significant leukemia growth delay. (A) % hCD45 + cells in peripheral blood at start of treatment (week 0), 1 and 2 weeks after start of treatment analyzed using flow cytometry. (B) % hCD45 + cells in bone marrow at end of treatment (2 weeks) analyzed using flow cytometry. (C) Spleen weight at end of treatment (2 weeks). ** P <0.01, **** P <0.0001.

    Article Snippet: At regular timepoints, % hCD45 (130-114-569, Miltenyi Biotec) was measured using flow cytometry (BD LSR II Flow Cytometer) in peripheral blood (PB).

    Techniques: Inhibition, In Vivo, Flow Cytometry

    T-LBL PDX models are sensitive towards in vivo treatment with decitabine. ( A ) T-LBL develops in lymphatic tissues such as the lymph nodes. In T-LBL cells, the DNA methylation pattern is hypermethylated compared to healthy cells. Upon replication, decitabine (DAC) can incorporate into the DNA and irreversibly bind to DNA methyl transferases (DNMTs), thereby countering hypermethylation and restoring transcription. Figure created with BioRender.com . ( B ) NSG mice injected with malignant pleural effusions from patients with T-LBL were treated with vehicle (PBS with 1% DMSO, blue) or decitabine (DAC 0.5 mg/kg body weight, orange). Once engraftment was successful (1% hCD45 + cells in the peripheral blood), mice were treated for one or two cycles for five consecutive treatment days followed by two days off. Mice were followed for survival analysis and leukemia burden in the blood. Figure created with BioRender.com . ( C ) Kaplan–Meier analysis of lymphoma-free survival after decitabine treatment (start of treatment is marked with a syringe) is shown (log-rank Mantel-Cox test; p -values: 0.1234 (ns), 0.0332 (*), 0.0021 (**), 0.0002 (***)) for the five T-LBL PDX models analyzed. One treatment cycle (dotted lines) and two treatment cycles (full lines) are compared. ( D ) The treatment effect of 1 cycle of decitabine on hCD45 + cells in the peripheral blood is shown by normalizing tumor growth (average #hCD45 + cells on day 5/average #hCD45 + cells on day 1) in decitabine treated mice to tumor growth in vehicle treated mice.

    Journal: Cancers

    Article Title: Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma

    doi: 10.3390/cancers15030647

    Figure Lengend Snippet: T-LBL PDX models are sensitive towards in vivo treatment with decitabine. ( A ) T-LBL develops in lymphatic tissues such as the lymph nodes. In T-LBL cells, the DNA methylation pattern is hypermethylated compared to healthy cells. Upon replication, decitabine (DAC) can incorporate into the DNA and irreversibly bind to DNA methyl transferases (DNMTs), thereby countering hypermethylation and restoring transcription. Figure created with BioRender.com . ( B ) NSG mice injected with malignant pleural effusions from patients with T-LBL were treated with vehicle (PBS with 1% DMSO, blue) or decitabine (DAC 0.5 mg/kg body weight, orange). Once engraftment was successful (1% hCD45 + cells in the peripheral blood), mice were treated for one or two cycles for five consecutive treatment days followed by two days off. Mice were followed for survival analysis and leukemia burden in the blood. Figure created with BioRender.com . ( C ) Kaplan–Meier analysis of lymphoma-free survival after decitabine treatment (start of treatment is marked with a syringe) is shown (log-rank Mantel-Cox test; p -values: 0.1234 (ns), 0.0332 (*), 0.0021 (**), 0.0002 (***)) for the five T-LBL PDX models analyzed. One treatment cycle (dotted lines) and two treatment cycles (full lines) are compared. ( D ) The treatment effect of 1 cycle of decitabine on hCD45 + cells in the peripheral blood is shown by normalizing tumor growth (average #hCD45 + cells on day 5/average #hCD45 + cells on day 1) in decitabine treated mice to tumor growth in vehicle treated mice.

    Article Snippet: Lymphoma engraftment was regularly monitored by flow cytometry, using human CD45 + (hCD45) staining (CD45-FITC antibody (Miltenyi Biotec, Bergish Gladbag, Germany)).

    Techniques: In Vivo, DNA Methylation Assay, Injection

    Characterization of the chimeric immune system.

    Journal: PLoS ONE

    Article Title: Anti-Proteinase 3 Anti-Neutrophil Cytoplasm Autoantibodies Recapitulate Systemic Vasculitis in Mice with a Humanized Immune System

    doi: 10.1371/journal.pone.0028626

    Figure Lengend Snippet: Characterization of the chimeric immune system.

    Article Snippet: Leukocytes were labelled with the following antibodies all at 1∶200 dilution: anti-hCD45-FITC, or –PE, hCD3-FITC, anti-hCD56-Al488 anti-hCD16-PE, anti-CD11b-APC, -PE or -FITC, anti-mCD45-FITC or -PE anti-mB220-APC (EBioscience), anti-hCD14-Alexa647, anti-hCD19-APC, anti-hCD15-FITC, anti-hCD66b-FITC (Biolegend), anti-Ly6C-FITC (BD Pharmingen).

    Techniques:

    (A–D) Flow cytometric analysis of leukocytes from tail bleeds six weeks after administration of HSCs (n = 26 mice). (A) Plots showing mouse leukocytes labelled with anti-mouse CD45 antibodies. Compared with control wild-type mouse blood, chimeras have populations of mCD45 negative leukocytes that show SSC characteristics of granulocytes (High), monocytes (Int) and lymphocytes (low). (B) Chimera blood leukocytes express human CD45 and many of these express CD11b. hCD45+,CD11b+ leukocytes predominantly express hCD15 and hCD66b compared with hCD45+,CD11b− leukocytes shown in histograms. (C) A proportion of hCD45+ leukocytes express CD19. (D) Some hCD45 leukocytes are CD14 high and some are CD16+,CD14 low . (E) In chimera bone marrow there are CD11b+ leukocytes which do not express mCD45 and among hCD45+ leukocytes a proportion express CD14 and a proportion express CD66b. (F) In chimera spleen there are CD11b+ leukocytes which express hCD45 and among hCD45+ leukocytes many express both CD14 and CD16. (G) Bone marrow spreads from wild type or chimera mice, labelled with anti-hMPO or anti-hPR3 IgG antibodies (red) purified from patients with vasculitis. Note that chimera bone marrow demonstrates anti-hMPO or anti-hPR3 antibody positive leukocytes with characteristic human neutrophil nuclear morphology. Wild type mouse bone marrow shows no cells positive for these antigens indicating that the anti-human antibodies do not cross react with mouse neutrophils.

    Journal: PLoS ONE

    Article Title: Anti-Proteinase 3 Anti-Neutrophil Cytoplasm Autoantibodies Recapitulate Systemic Vasculitis in Mice with a Humanized Immune System

    doi: 10.1371/journal.pone.0028626

    Figure Lengend Snippet: (A–D) Flow cytometric analysis of leukocytes from tail bleeds six weeks after administration of HSCs (n = 26 mice). (A) Plots showing mouse leukocytes labelled with anti-mouse CD45 antibodies. Compared with control wild-type mouse blood, chimeras have populations of mCD45 negative leukocytes that show SSC characteristics of granulocytes (High), monocytes (Int) and lymphocytes (low). (B) Chimera blood leukocytes express human CD45 and many of these express CD11b. hCD45+,CD11b+ leukocytes predominantly express hCD15 and hCD66b compared with hCD45+,CD11b− leukocytes shown in histograms. (C) A proportion of hCD45+ leukocytes express CD19. (D) Some hCD45 leukocytes are CD14 high and some are CD16+,CD14 low . (E) In chimera bone marrow there are CD11b+ leukocytes which do not express mCD45 and among hCD45+ leukocytes a proportion express CD14 and a proportion express CD66b. (F) In chimera spleen there are CD11b+ leukocytes which express hCD45 and among hCD45+ leukocytes many express both CD14 and CD16. (G) Bone marrow spreads from wild type or chimera mice, labelled with anti-hMPO or anti-hPR3 IgG antibodies (red) purified from patients with vasculitis. Note that chimera bone marrow demonstrates anti-hMPO or anti-hPR3 antibody positive leukocytes with characteristic human neutrophil nuclear morphology. Wild type mouse bone marrow shows no cells positive for these antigens indicating that the anti-human antibodies do not cross react with mouse neutrophils.

    Article Snippet: Leukocytes were labelled with the following antibodies all at 1∶200 dilution: anti-hCD45-FITC, or –PE, hCD3-FITC, anti-hCD56-Al488 anti-hCD16-PE, anti-CD11b-APC, -PE or -FITC, anti-mCD45-FITC or -PE anti-mB220-APC (EBioscience), anti-hCD14-Alexa647, anti-hCD19-APC, anti-hCD15-FITC, anti-hCD66b-FITC (Biolegend), anti-Ly6C-FITC (BD Pharmingen).

    Techniques: Purification

    Kidney sections were incubated with anti-mCD45 (red) and anti-hCD45 (green) antibodies and images were captured by fluorescence microscopy (T = tubule). Occasional (<5%) glomeruli of anti-PR3 treated mice displayed intense extracapillary leukocyte infiltration (A) in the shape of crescents (arrows). Most glomeruli in animals treated with anti-PR3 antibodies (n = 18) had evidence of intraglomerular (B,G) and peri-glomerular (C,G) leukocyte infiltration. These were comprised mostly of mCD45+ cells, although some hCD45 leukocytes were also present (arrowheads). In addition, there was a significant increase in peri-vascular leukocyte (mCD45+ and hCD45+) infiltration in anti-PR3 treated mice (D,G [per arteriolar section (art.sec.)]). Sections were also stained for deposition of IgG [red] (E,G) and C3 [green] (F,G). IgG was detectable within periglomerular cells, but there was minimal deposition within the glomeruli. Mouse C3 was weakly deposited in glomeruli but was no different between control group (n = 8) and anti-PR3 group (n = 18). Note mouse C3 can be detected normally binding avidly to tubular basement membranes. (Marker = 10 µm) (* P <0.05, ** P <0.01. median ± IQ ± max/min values). (H) Kidney sections from anti-PR3 and control treated animals were incubated with anti-PR3 positive ANCA IgG. In the peritubular capillaries of chimera mice that received anti-PR3 hIgG occasional leukocytes detected by anti-hPR3 hIgG could be detected. No positively stained human neutrophils were seen in glomeruli.

    Journal: PLoS ONE

    Article Title: Anti-Proteinase 3 Anti-Neutrophil Cytoplasm Autoantibodies Recapitulate Systemic Vasculitis in Mice with a Humanized Immune System

    doi: 10.1371/journal.pone.0028626

    Figure Lengend Snippet: Kidney sections were incubated with anti-mCD45 (red) and anti-hCD45 (green) antibodies and images were captured by fluorescence microscopy (T = tubule). Occasional (<5%) glomeruli of anti-PR3 treated mice displayed intense extracapillary leukocyte infiltration (A) in the shape of crescents (arrows). Most glomeruli in animals treated with anti-PR3 antibodies (n = 18) had evidence of intraglomerular (B,G) and peri-glomerular (C,G) leukocyte infiltration. These were comprised mostly of mCD45+ cells, although some hCD45 leukocytes were also present (arrowheads). In addition, there was a significant increase in peri-vascular leukocyte (mCD45+ and hCD45+) infiltration in anti-PR3 treated mice (D,G [per arteriolar section (art.sec.)]). Sections were also stained for deposition of IgG [red] (E,G) and C3 [green] (F,G). IgG was detectable within periglomerular cells, but there was minimal deposition within the glomeruli. Mouse C3 was weakly deposited in glomeruli but was no different between control group (n = 8) and anti-PR3 group (n = 18). Note mouse C3 can be detected normally binding avidly to tubular basement membranes. (Marker = 10 µm) (* P <0.05, ** P <0.01. median ± IQ ± max/min values). (H) Kidney sections from anti-PR3 and control treated animals were incubated with anti-PR3 positive ANCA IgG. In the peritubular capillaries of chimera mice that received anti-PR3 hIgG occasional leukocytes detected by anti-hPR3 hIgG could be detected. No positively stained human neutrophils were seen in glomeruli.

    Article Snippet: Leukocytes were labelled with the following antibodies all at 1∶200 dilution: anti-hCD45-FITC, or –PE, hCD3-FITC, anti-hCD56-Al488 anti-hCD16-PE, anti-CD11b-APC, -PE or -FITC, anti-mCD45-FITC or -PE anti-mB220-APC (EBioscience), anti-hCD14-Alexa647, anti-hCD19-APC, anti-hCD15-FITC, anti-hCD66b-FITC (Biolegend), anti-Ly6C-FITC (BD Pharmingen).

    Techniques: Incubation, Fluorescence, Microscopy, Staining, Binding Assay, Marker